XClose

UCL Division of Surgery and Interventional Science

Home
Menu

Urology

Our aim is to improve and optimise the care of those affected by urological conditions and increase our research reach and impact. This includes the PRIME Trial, which is investigating the use of bi-parametric MRI in the diagnosis of prostate cancer.

Our work

YouTube Widget Placeholderhttps://www.youtube.com/watch?v=J6OszGI85wI

Our experts

Caroline Moore

Prof. Caroline Moore

Clément Orczyk

Clément Orczyk

John Kelly

Prof. John Kelly

Maxine Tran

Maxine Tran

Veeru Kasivisvanathan

Veeru Kasivisvanathan

 

Select publications

  1. Khetrapal, P., Stafford, R., Ó Scanaill, P., Kocadag, H., Kelly, J.D., et al. (2022). Measuring Patient Compliance With Remote Monitoring Following Discharge From Hospital After Major Surgery (DREAMPath): Protocol for a Prospective Observational Study. JMIR Research Protocols, 11 (4), e30638.
  2. Kasivisvanathan, V., Chan, V.W.S., Clement, K. D., Emberton, M., Moore, C.M., et al. (2022). A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prostate cancer. PLoS ONE, 17, e0263345.
  3. Ng, A., Khetrapal, P., Brew‐Graves, C., Muirhead, N., Kasivisvanathan, V., et al. (2022). Choosing appropriate patient‐reported outcome measures for prostate disease. BJUI Compass.
  4. Orczyk, C., Barratt, D., Brew-Graves, C., Peng Hu, Y., Emberton, M., et al. (2021). Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. J Urol, 101097JU0000000000001567.
  5. Tan, W.S. & Kelly, J.D. (2021). Is delay to radical cystectomy following BCG failure oncologically safe? Nature Reviews Urology.
  1. Stavrinides, V., Giganti, F., Orczyk, C., Emberton, M., Moore, C.M., et al. (2020). Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study. European Urology.
  2. Giganti, F., Stavrinides, V., Stabile, A., Orczyk, C., Emberton, M., Moore, C.M., et al. (2020). Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. Br J Radiol, 20200819.
  3. Stabile, A., Orczyk, C., Giganti, F., Emberton, M., Moore, C.M., et al. (2020). The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. Eur Urol.
  4. Giganti, F., Kirkham, A., Allen, C., Orczyk, C., Emberton, M. & Moore, C.M. (2020). Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations. The American journal of roentgenology, radium therapy, and nuclear medicine.
  5. Stabile, A., Orczyk, C., Hosking-Jervis, F., Giganti, F., Emberton, M., Moore, C.M., et al. (2019). Medium term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using HIFU for primary localized prostate cancer. BJU International.

PRIME Trial

Prime

Our study will assess if bi-parametric MRI can provide similar information to multiparametric MRI in the diagnosis of clinically significant prostate cancer.

ClinicalTrials.gov Identifier: NCT04571840

Current trial status: Recruiting Q1 2022

Frequently asked questions

The standard way to diagnose prostate cancer is a multiparametric MRI scan and targeted biopsy. This type of scan normally involves inserting a cannula into a vein to inject contrast.

Another type of MRI scan (bi-parametric) requires neither contrast nor cannula. This is an advantage because contrast carries a risk of allergy and potential side effects.

We are uncertain whether the bi-parametric span will allow us to detect the same levels of prostate cancer as the standard (multiparametric) MRI. Current evidence suggests it may detect similar amounts of cancer. If it proves to be as effective, this would be of benefit.

For this trial, patients will undergo a multiparametric MRI, the current standard diagnostic method. The reviewing doctor will be asked to review the MRI scan in a different order than usual to investigate whether bi-parametric MRI can offer the same degree of accuracy in detecting prostate cancer.

Members of the award-winning PRECISION team awarded the 2019 BMJ Research Paper of the Year for the PRECISION study.
Members of the award-winning PRECISION team awarded the 2019 BMJ Research Paper of the Year for the PRECISION study. The same team will be delivering the PRIME Study.

 

Are you a patient?

To participate, your GP must have referred you to hospital for further investigations for prostate cancer, such as an MRI scan. You may be approached to participate in the study if you meet the criteria. This is only applicable to sites that are taking part in the PRIME study. Provisionally, in the UK, these include UCLH, Royal Free, Whittington, and Addenbrooke's.

You can follow the progress of the trial and see which hospitals are recruiting for the study by checking this website regularly.

Are you an investigator?

With over 60 centres expressing interest and 30 going through the contract process, we are not currently taking on further sites. We hope to collaborate with you on future studies.

For more information, please contact ncita.prime@ucl.ac.uk or primestudy@ucl.ac.uk.

University College London NCITA Trials group

Chief Investigator: Mr Veeru Kasivisvanathan

  • Professor Caroline Moore
  • Dr Pramit Khetrapal
  • Dr Chris Brew-Graves
  • Professor Shonit Punwani
  • Mr Alexander Ng
  • Miss Aqua Asif
  • Mr Vinson Wai-Shun Chan
  • Mr Arjun Nathan
  • Miss Marimo Rossiter.

Key collaborators

  • Statistics by: University of Birmingham Test Evaluation Research Group, Dr Yemisi Takwoingi, Professor Jon Deeks.
  • EAU Research Foundation: Dr Wim Witjes, Ms Christien Caris, Professor Anders Bjartell.
  • Trial Network: PRECISION & START Consortium.

Sponsor: 

University College London (UCL)

Supported by: 

Cancer Research UK. The National Institute for Health Research

Funded by: 

EAU Research Foundation. The John Black Charitable Foundation. Prostate Cancer UK. The Dieckmann Foundation.

National Institute for Health Research (NIHR) Logo

dieckmann

John Black Charitable Foundation Logo

PCR

Cancer Research UK Logo

World experts in prostate cancer, part of the START consortium who are part of the group delivering the PRIME study.

EAURF Foundation, NCITA, and Birmingham univeristy logos